(Q66046395)
Statements
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001 (English)
0 references
4 April 2017
0 references
30 July 2018
0 references
84
0 references
18 year
0 references